22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › IOVANCE BIOTHERAPEUTICS INC. › 2024-2025

IOVANCE BIOTHERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and IOVANCE BIOTHERAPEUTICS INC.’s Form 8-K, filed June 10, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 11Reported items
  • 265Asset managers, any item
  • 2,301Fund votes
  • June 10, 2025Meeting date

Results at a glance

Meeting of June 10, 2025: 11 items on IOVANCE BIOTHERAPEUTICS INC.’s Form 8-K, filed June 10, 2025: 4 approved · 7 passed (calculated).

Dissent

Significant dissent: 1 director (43.4% against).

Notable dissent: 1 director (17.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IOVANCE BIOTHERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by IOVANCE BIOTHERAPEUTICS INC.

These tallies are IOVANCE BIOTHERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IOVANCE BIOTHERAPEUTICS INC. — official shareholder meeting results, meeting held June 10, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dr. Dukes 142,089,79530,706,3931,322,491 --80,162,659 82%Passed (calculated)—
Elect Director: Dr. Countouriotis 97,767,91775,070,0201,280,742 --80,162,659 57%Passed (calculated)—
Elect Director: Mr. Maynard 166,367,8696,453,5381,297,272 --80,162,659 96%Passed (calculated)—
Elect Director: Mr. Rothbaum 166,890,3796,038,2841,190,016 --80,162,659 97%Passed (calculated)—
Elect Director: Dr. Vogt 165,079,1378,467,205572,337 --80,162,659 95%Passed (calculated)—
Elect Director: Dr. Weiser 165,295,5357,540,9401,282,204 --80,162,659 96%Passed (calculated)—
Elect Director: Ms. Yarno 166,781,3245,674,4321,662,923 --80,162,659 97%Passed (calculated)—
This proposal was approved with 158,778,895 "FOR" votes, 14,490,865 "AGAINST" votes and 848,919 "ABSTAIN" votes 158,778,89514,490,865848,919 --80,162,659 92%Approved—
This proposal was approved with 248,444,246 "FOR" votes, 4,930,624 "AGAINST" votes and 906,468 "ABSTAIN" votes 248,444,2464,930,624906,468 --0 98%Approved—
This proposal was approved with 160,920,940 "FOR" votes, 12,607,644 "AGAINST" votes and 590,095 "ABSTAIN" votes 160,920,94012,607,644590,095 --80,162,659 93%Approved—
This proposal was approved with 163,851,673 "FOR" votes, 9,804,728 "AGAINST" votes and 462,278 "ABSTAIN" votes 163,851,6739,804,728462,278 --80,162,659 94%Approved—

Source: IOVANCE BIOTHERAPEUTICS INC., Form 8-K, filed with the SEC on June 10, 2025 — read the filing on EDGAR.

How asset managers voted at the IOVANCE BIOTHERAPEUTICS INC. 2024-2025 meeting

265 asset managers disclosed a vote on at least one IOVANCE BIOTHERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of IOVANCE BIOTHERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Dr. Countouriotis

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

57% Majority: yes · of votes cast

FOR 57%AGAINST
FOR: 97,767,917AGAINST: 75,070,020
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Athena Countouriotis, M.D.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Countouriotis”): 97,767,917 for, 75,070,020 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 57% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 6,093,079 for, 48,604,029 against, 27,255 abstained.

AGAINST
FOR: 6,093,079AGAINST: 48,604,029ABSTAIN: 27,255
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Athena Countouriotis, M.D.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10127,857,904 00Against
BlackRock07,151,892 00Against
Delaware/Macquarie04,081,508 00Against
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price02,430,276 00Against
Principal6112,094,700 00Against
Charles Schwab1,871,6040 00For
TIAA0817,117 00Against
Equitable0610,583 00Against
Fidelity0305,709 00Against
Manager Directed Portfolios302,8720 00For
Lincoln Financial0275,886 00Against
QUANTITATIVE MASTER SERIES LLC0270,099 00Against
State Street738269,003 00Against
Virtus0177,635 00Against
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC0160,900 00Against
RMB INVESTORS TRUST0157,696 00Against
Guggenheim0150,408 00Against
John Hancock0147,607 00Against
Direxion Shares ETF Trust0145,798 00Against
ProShares0145,497 00Against
AIG/SunAmerica0140,283 00Against
Aberdeen131,8000 00For
Northern Trust129,1980 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: Dr. Vogt

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 165,079,137AGAINST: 8,467,205
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Vogt”): 165,079,137 for, 8,467,205 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 54,697,108 for, 0 against, 27,255 abstained.

FOR
FOR: 54,697,108AGAINST: 0ABSTAIN: 27,255
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For
Northern Trust129,1980 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: Dr. Dukes

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%AGAINST
FOR: 142,089,795AGAINST: 30,706,393
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: lain Dukes, D. Phil.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Dukes”): 142,089,795 for, 30,706,393 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 41,893,482 for, 12,803,626 against, 27,255 abstained.

FORAGAINST
FOR: 41,893,482AGAINST: 12,803,626ABSTAIN: 27,255
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: lain Dukes, D. Phil.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,855,7912,214 00For
BlackRock408,1876,743,705 00Mixed
Delaware/Macquarie04,081,508 00Against
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable2,130608,453 00Against
Fidelity211,98993,720 00Mixed
Manager Directed Portfolios302,8720 00For
Lincoln Financial75,186200,700 00Mixed
QUANTITATIVE MASTER SERIES LLC0270,099 00Against
State Street1,062268,679 00Against
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For
Northern Trust0129,198 00Against

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: Dr. Weiser

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 165,295,535AGAINST: 7,540,940
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Weiser”): 165,295,535 for, 7,540,940 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 54,511,283 for, 185,825 against, 27,255 abstained.

FOR
FOR: 54,511,283AGAINST: 185,825ABSTAIN: 27,255
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,855,7912,214 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For
Northern Trust129,1980 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: Mr. Maynard

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 166,367,869AGAINST: 6,453,538
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Ryan Maynard

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Maynard”): 166,367,869 for, 6,453,538 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 54,542,338 for, 154,770 against, 27,255 abstained.

FOR
FOR: 54,542,338AGAINST: 154,770ABSTAIN: 27,255
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Ryan Maynard” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For
Northern Trust129,1980 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: Mr. Rothbaum

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 166,890,379AGAINST: 6,038,284
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wayne P. Rothbaum

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Rothbaum”): 166,890,379 for, 6,038,284 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 54,542,338 for, 154,770 against, 27,255 abstained.

FOR
FOR: 54,542,338AGAINST: 154,770ABSTAIN: 27,255
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wayne P. Rothbaum” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For
Northern Trust129,1980 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: Ms. Yarno

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 166,781,324AGAINST: 5,674,432
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wendy Yarno

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Ms. Yarno”): 166,781,324 for, 5,674,432 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 54,697,108 for, 0 against, 27,255 abstained.

FOR
FOR: 54,697,108AGAINST: 0ABSTAIN: 27,255
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wendy Yarno” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For
Northern Trust129,1980 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common…

No official matchCOMPENSATION

Combines 2 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 65 asset managers

Description as filed by funds: To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 12,500,000 shares; and

The 65 asset managers below reported 54,619,134 for, 77,974 against, 27,255 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 54,619,134AGAINST: 77,974ABSTAIN: 27,255
Largest asset managers voting on “To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's co” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7365 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For
Northern Trust129,1980 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

To approve an amendment to our 2020 employee stock purchase plan to increase the number of shares of the company's…

No official matchCOMPENSATION

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 65 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR 2020 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 1,000,000 SHARES.

The 65 asset managers below reported 54,697,108 for, 27,255 against, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 54,697,108AGAINST: 27,255ABSTAIN: 0
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR 2020 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES OF THE COMPA” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For
Northern Trust129,1980 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

To approve, by non-binding advisory vote, the compensation of our named executive officers.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 10 wordings of this item as funds reported it.

97% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 264 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 64 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,855,7772,228 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable352,793257,790 00Mixed
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,343398 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen0131,800 00Against
Northern Trust129,1980 00For

Fund voting reports, all 64 managers: 54,185,930 for, 511,178 against, 27,255 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 215 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
MHR FUND MANAGEMENT LLC24,417,1030 00For
Invenomic Capital Management LP6,574,3990 00For
BlackRock6,033,91243,272 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST4,505,3630 00For
Hood River Capital Management LLC3,914,6440 00For
T. Rowe Price3,413,9110 00For
Palo Alto Investors LP3,032,2090 00For
PRINCIPAL GLOBAL INVESTORS3,010,0850 00For
State Street2,698,8741,058 00For
Soleus Capital Management, L.P.1,906,9620 00For
Charles Schwab1,871,6390 00For
BANK OF AMERICA NA1,298,1110 00For
C WorldWide Asset Management Fondsmaeglerselskab A/S01,260,000 00Against
Northern Trust1,242,1990 00For
RICE HALL JAMES & ASSOCIATES, LLC1,124,1950 00For
APIS CAPITAL ADVISORS, LLC1,098,1300 00For
Nuveen836,0180 00For
UBS0774,375 00Against
Vanguard758,7680 00For
PICTET ASSET MANAGEMENT SA705,3190 00For
MPM BioImpact LLC647,4920 00For
Allianz0606,361 00Against
JACOBS LEVY EQUITY MANAGEMENT, INC539,7030 00For
RBC Capital Markets, LLC504,6400 00For
MELLON INVESTMENTS Corp0476,611 00Against

Institutional-manager reports, all 215 managers: 74,550,881 for, 3,961,348 against, 161,143 abstained, 129,705 not voted. Showing the 25 largest; every one is in the interactive database (link above).

To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year…

No official matchAUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 64 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;

The 64 asset managers below reported 54,697,108 for, 0 against, 27,255 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 54,697,108AGAINST: 0ABSTAIN: 27,255
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fi” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For
Northern Trust129,1980 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Largest IOVANCE BIOTHERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 333,934,387 shares outstanding at the time of that meeting.

Fund voting reports: top IOVANCE BIOTHERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 8.34%
2BlackRock 2.14%
3Delaware/Macquarie 1.22%
4NORTHERN LIGHTS FUND TRUST II 0.98%
5T. Rowe Price 0.73%
6Principal 0.63%
7Charles Schwab 0.56%
8TIAA 0.24%
9Equitable 0.18%
10Fidelity 0.09%
Institutional-manager reports: top IOVANCE BIOTHERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1MHR FUND MANAGEMENT LLC 7.31%
2Invenomic Capital Management LP 1.97%
3BlackRock 1.82%
4MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST 1.35%
5Hood River Capital Management LLC 1.17%
6T. Rowe Price 1.02%
7Palo Alto Investors LP 0.91%
8PRINCIPAL GLOBAL INVESTORS 0.90%
9State Street 0.81%
10Soleus Capital Management, L.P. 0.57%

Reported IOVANCE BIOTHERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

IOVANCE BIOTHERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
New York, NY30,000,000 8.98%Proxy statement (DEF 14A), proxy filed April 28, 2025
Wayne Rothbaum30,000,000 8.98%Proxy statement (DEF 14A), proxy filed April 28, 2025
Vanguard Group27,777,778 8.32%Form 13F, quarter ended March 31, 2025
BlackRock24,314,578 7.28%Form 13F, quarter ended March 31, 2025
Malvern, PA22,812,820 6.83%Proxy statement (DEF 14A), proxy filed April 28, 2025
State Street11,041,322 3.31%Form 13F, quarter ended March 31, 2025
Geode Capital5,968,298 1.79%Form 13F, quarter ended March 31, 2025
Goldman Sachs5,571,902 1.67%Form 13F, quarter ended March 31, 2025
Morgan Stanley4,018,374 1.20%Form 13F, quarter ended March 31, 2025
Renaissance Technologies3,511,400 1.05%Form 13F, quarter ended March 31, 2025

Percentages above are of 333,934,387 shares outstanding, as reported by IOVANCE BIOTHERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At IOVANCE BIOTHERAPEUTICS INC.'s shareholder meeting held June 10, 2025, in the 2024-2025 proxy season, 265 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 2,301 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. IOVANCE BIOTHERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, by non-binding advisory vote, the compensation of our named executive officers. — the reporting funds and managers cast 97% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IOVANCE BIOTHERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

IOVANCE BIOTHERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “IOVANCE BIOTHERAPEUTICS (IOVA) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/iovance-biotherapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.